(Q41732517)

8 October 2017

1 reference

title

Restoring function in failing hearts: the effects of beta blockers (English)

1 reference

8 October 2017

Eichhorn EJ

1

1 reference

8 October 2017

language of work or name

English

0 references

publication date

1 February 1998

1 reference

American Journal of Medicine

8 October 2017

published in

1 reference

8 October 2017

volume

104

1 reference

8 October 2017

issue

2

1 reference

8 October 2017

page(s)

163-169

1 reference

Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

The role of cyclic AMP in isoprenaline-induced cardiac necroses in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Prostacyclin therapy in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

The paradox of beta-adrenergic blockade for the management of congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Beta-blocker treatment for chronic heart failure. The frog prince

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Beta-blockers in heart failure: promising or proved?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Usefulness of bucindolol in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Double-Blind, Placebo-Controlled Study of the Long-term Efficacy of Carvedilol in Patients With Severe Chronic Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Why do patients with congestive heart failure tolerate the initiation of beta-blocker therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Cellular mechanisms in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1- and beta-adrenoceptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Ventricular remodelling: consequences and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Wall stress and patterns of hypertrophy in the human left ventricle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Reductions in muscle sympathetic nerve activity after long-term metoprolol for dilated cardiomyopathy: preliminary observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effects of bucindolol on neurohormonal activation in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Adrenergic effects on the biology of the adult mammalian cardiocyte

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900171-X

10.1016/S0002-9343(97)00171-X

7 January 2021

Identifiers

DOI

1 reference

8 October 2017

1 reference